Asahi Kasei Medical To Double Virus Filter Production
This article was originally published in PharmAsia News
Executive Summary
Asahi Kasei Medical announced Jan. 30 a plan to double its production capacity for virus filters. The company will invest ¥2.5 billion and establish a second production line at its facility in Oita city by March 2010. Widely used in the pharmaceutical production process, the filters are able to deactivate HIV or hepatitis virus mixed in animal by-products used as pharmaceutical materials. According to the company, the demand from the U.S. and Europe has been increasing. (Click here for more - Japanese language
You may also be interested in...
Asahi Kasei Acquires U.S.-based Device Maker TechniKrom; Seeks ¥18 Billion in Sales
TOKYO - Asahi Kasei Medical, a unit of Japan's Asahi Kasei, has reached an agreement to fully acquire TechniKrom, a bioprocess equipment manufacturer, in a merger that the company hopes will spark growth between its filtering technology and the U.S. firm's bioprocess equipment systems for biopharmaceutical manufacturing materials, the Japanese parent company announced Feb. 16
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.